GLAUKOS Corp (New York Stock Exchange:GKOS)
| Market Cap | $14.05B+138.2% |
| Revenue (ttm) | $690.33M+46.9% |
| Net Income | -$169.80M-93.8% |
| EPS | -$2.94-90.9% |
| Shares Out | 59.20M |
| PE Ratio | n/a |
| Forward PE | 169.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,089,555 |
| Open | $237.34 |
| Previous Close | $238.10 |
| Day's Range | $233.27 - $244.48 |
| 52-Week Range | $93.96 - $255.19 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | $225.55(-4.96%) |
| Earnings Date | Feb 16, 2027 |
About GKOS
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
10 firms rating GKOS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 16, 2027Earnings report
$GKOS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in GKOS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GKOS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GKOS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GKOS Revenue by Segment or Geography
| Glaucoma | $151.99M | 72.02% |
| Corneal Health | $59.04M | 27.98% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GKOS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GKOS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GKOS
| IJHiShares Core S&P Mid-Cap ETF | $506.09M |
| IWMiShares Russell 2000 ETF | $359.95M |
| VTIVanguard Morningstar Total Stock Market ETF | $333.51M |
| VBVanguard Morningstar Small-Cap ETF | $298.48M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $167.09M |
| VXFVanguard Extended Market ETF | $159.02M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from GKOS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive valuation thesis and ETF accumulation activity outweigh single passive selling note; contrarian analyst vindication suggests bullish re-rating potential.
Recent Insider Activity
Insider Score Trend Over Time
-35.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| NBDS | Neuberger Berman Disrupters ETF | 5.92% |
| FCUS | Pinnacle Focused Opportunities ETF | 4.56% |
| SGRT | SMART Earnings Growth 30 ETF | 2.95% |
| HYP | Golden Eagle Dynamic Hypergrowth ETF | 2.78% |
| ARWG | Archer Growth ETF | 2.77% |
| PCSG | Polen 5Perspectives Small-Mid Growth ETF | 2.57% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 2.26% |
| XHE | State Street SPDR S&P Health Care Equipment ETF | 2.08% |
| GSC | Goldman Sachs Small Cap Equity ETF | 1.81% |
| IHI | iShares U.S. Medical Devices ETF | 1.80% |
| SAWS | AAM Sawgrass U.S. Small Cap Quality Growth ETF | 1.73% |
| CTAG | Calamos Timpani Active SMID Growth ETF | 1.57% |
Weight is the stock’s share of each fund’s holdings.
